Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit!
If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Accurately Predict & Measure Immune Response with Validated Immunoassays and Monitor & Mitigate Against Adverse Events to Deliver Clinically Safe & Effective Gene Therapies
Optimize Safety & De-Risk Efficacy of Viral Vector Based Gene Therapies
The 5th Gene Therapy Immunogenicity Summit was created for gene therapy developers focussed on predicting, preventing, monitoring, and mitigating adverse immune responses to AAV gene therapy including:
Translational Medicine
Pharmacology
Non-Clinical Development
Toxicology
Clinical Development
Bioanalysis
The success of gene therapy hinges on overcoming the immunogenicity challenges of viral vectors. With more AAV based gene therapies progressing through the pipeline, we need to seek solutions to this critical bottleneck ‘here and now’.
The 5th Gene Therapy Immunogenicity Summit returned to Boston this August, bringing together the leading immunogenicity experts responsible for predicting, measuring, and mitigating immune response. Delegates shared their learnings and gained key insights on:
- Promoting AAV safety whilst maintaining efficacy
- Preventing the immunogenicity related bottlenecks slowing gene therapy development
- Case-study-led examples across immunogenicity and ask big-hitting immunology questions to your peers actively working in the space to make clinically safe and effective gene therapies a reality
- Predicting and mitigating against complement activation and other toxicity issues with Ask Bio, Takeda, and Novartis
- Validating novel Immunoassays, bioanalytical and biodistribution technology with Astellas Gene Therapies and Boehringer Ingelheim
- Understanding possible risks around exacerbation of both the innate and adaptive immune response with Roche and Tenaya Therapeutics
- Exploring the practicalities of AAV redosing through an immunology lens with the University of Indiana and Adolore Biotherapeutics
- Examine the immunogenicity risks specific to gene editing approached as momentum in the field increases with CRISPR and Modalis Therapeutics
Our pre-conference workshop day was a great opportunity to have in-depth discussions with peers on a range of preclinical, translational and clinical topics such as preclinical toxicology studies, immunosuppression & immunomodulation, immunoassays and redosing gene therapies.
2024 Speaker Faculty Included:
Previously Attending Companies Include:
Testimonials:
“Variety of topics was good. And the mix of preclinical and clinical presentations. One of the things that made it most enjoyable was the small intimate setting and ability to talk with many attendees.”
Sharon McGonigle, VP-R&D
"Very insightful talks broad enough to cover everything while still having depth. All speakers were knowledgeable and the discussions were helpful.”
Anne Ogbe, Group Lead – Translational, Clinical & Regulatory
2024 Partners:
Other Events in the Series
